Affiliation:
1. Department of Otorhinolaryngology and Head and Neck Surgery, All India Institute of Medical Sciences, Bibinagar,
Hyderabad, India
Abstract
Abstract:
Thyroid cancer is the fifth most prevalent cancer in women and the fastest-growing
malignancy. Although surgery is still the basis of treatment, internal radiation therapy
[Brachytherapy] with radioactive iodine-131, which functions by releasing beta particles with
low tissue penetration and causing DNA damage, is also a potential option. The three basic aims
of RAI therapy in well-differentiated thyroid tumors are ablation of the remnant, adjuvant
therapy, and disease management. Radioactive iodine dose is selected in one of two ways,
empiric and dosimetric, which relies on numerous criteria. The dosage for ablation is 30-100
mCi, 30-150 mCi for adjuvant therapy, and 100-200 mCi for treatment. The RAI treatment
effectively aids in the treatment to achieve complete removal of the disease and increase
survival. The present review intends to emphasize the significance of radioactive iodine in the
management of differentiated thyroid cancer and put forward the current breakthroughs in
therapy.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology,Radiology, Nuclear Medicine and imaging